NCT04083482

Brief Summary

The plasma level of mtDNA in sepsis is affected by continous venovenous hemofiltation（CVVH）

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 20, 2018

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2018

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

September 3, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 10, 2019

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

September 10, 2019

Status Verified

September 1, 2019

Enrollment Period

1 month

First QC Date

September 3, 2019

Last Update Submit

September 5, 2019

Conditions

Intensive Care Unit

Keywords

Mitochondrial DNASepsisContinous venovenous hemofiltationIntensive Care Unit

Outcome Measures

Primary Outcomes (1)

  • Change of mtDNA concentration in plasma

    The specimens in the prefilter and postfilter blood as well as in the ultrafiltrate were obtained at the beginning of CRRT (T0) and 6 h (T6h), 12 h (T12h) after the setup of CVVH.

    befor,6hours, 12hours, after CVVH treatment

Study Arms (1)

Septic patients require CVVH

EXPERIMENTAL

continuous venovenous hemofiltration. Continuous renal replacement therapy（CRRT）has become routine for patients with chronic renal failure ，AKI，fliud overload as well as oliguria in ICU .Continuous venovenous hemofiltration（CVVH）is the method of chioce for CRRT in critical ill .CVVH has significant beneficial effects on removing inflammatory cytokines ，improving oxygen index ，decreasing vasopressor requirements，increasing cardiac index and regulating immune dysfunction .

Procedure: continous venovenous hemofiltraion

Interventions

continous venovenous hemofiltraionPROCEDURE

CVVH

Septic patients require CVVH

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult septic patients undergoing CRRT

You may not qualify if:

  • Missing vists
  • transplatation
  • cancer
  • aquired immunodeficiency syndrome

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Hospital of Chenzhou

Chenzhou, Hunan, 450003, China

Location

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • dixian luo, MS

    Chenzhou First people Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Critical Care Medicine

Study Record Dates

First Submitted

September 3, 2019

First Posted

September 10, 2019

Study Start

August 20, 2018

Primary Completion

September 20, 2018

Study Completion

December 31, 2019

Last Updated

September 10, 2019

Record last verified: 2019-09

Locations

CN(1)